Next-generation medical devices for neurovascular disease


About Us


Oxford Endovascular Ltd is a spin-out from Oxford University, working to prevent brain haemorrhage by curing brain aneurysms, a condition that affects 1 in 50 persons.

OxiFlow™️ is a novel, next generation flow-diverter, that diverts blood flow away from intracranial aneurysms at risk of rupture. It places more accurately and safely than existing devices, reducing the risk of complications. It conforms better to blood vessels making more patients treatable

Our Mission


Invented by a world-renowned physician who pioneered the treatment of aneurysms over the last 30 years and an expert in ‘origami engineering’, it has patents in Europe, US, China & Japan.

The company has raised over $10m to support its development including winning a prestigious Horizon 2020 grant from the European Union following extensive due diligence by medical, industry and investor experts.

Targeting a market over $1 billion, that is growing rapidly, Oxford Endovascular is poised for significant increased value as it addresses unmet clinical needs.

Team of Success


CEO - Mike Karim

Over 30 years of international experience in medical devices including endovascular products. Leadership roles in general management, sales & marketing and mentoring. Success in fund raising, driving business growth in large corporations, SMEs and start ups, developing and bringing new products to market.



Chairman - Chas Taylor

Experienced serial entrepreneur who has founded, led and successfully sold three MedTech companies (Veryan, Novate, MedNova), raising in excess of £100m funding from private, Venture Capital, Venture Debt and Corporate sources. Has mentored multiple businesses delivering value creation through development, regulatory and commercial strategies.


Non-exec Director - Brian Howlett

Long career as a medtech business leader including with endovascular products. Board member of three emerging medtech companies, CEO of Lombard Medical Technologies (2005-2009), General Manager of Boston Scientific in UK (1999-2005)


Clinical Director - James Byrne

Professor of Neuroradiology & Consultant Neuroradiologist with over 30 years of clinical experience treating aneurysm patients. Led over 30 courses training MDs to treat aneurysms and has a track record in prototype development and device testing.


Technology Director - Zhong You

Professor of Engineering Science and an expert in origami structures & minimally invasive medical devices. Gained funding from the Wellcome Trust Centre of Excellence to develop prototype medical devices.

News & Events


 

Oxford Endovascular named as one of the UK’s 10 coolest HealthTech start-ups!

  https://www.uktech.news/news/coolest-uk-healthtech-startups-in-2021-20210628?
Read More
Oxford Endovascular named as one of the UK’s 10 coolest HealthTech start-ups!

Oxford Endovascular Ltd raises $10m to develop its origami engineered medical device to prevent brain haemorrhage

Funding will support the company to achieve first-in-human data Oxford, UK, 8th April 2021 - Oxford Endovascular, a pioneering British...
Read More
Oxford Endovascular Ltd raises $10m to develop its origami engineered medical device to prevent brain haemorrhage

Oxford Endovascular wins Innovate UK Smart Grant

Press Release: Oxford, UK, 14th November 2020.   Oxford Endovascular Ltd, the developer of advanced neurovascular technologies to save lives...
Read More
Oxford Endovascular wins Innovate UK Smart Grant

Oxford Endovascular wins support from EIT Health as one of Europe’s top start-ups!

Following extensive due diligence by medical, industry, and investor experts, Oxford Endovascular is selected as one of Europe's top start-ups...
Read More
Oxford Endovascular wins support from EIT Health as one of Europe’s top start-ups!

Oxford Endovascular is chosen as a finalist in the RESI Innovation challenge!

This kick starts the company's next fundraise to take it to first in human clinical data. See the RESI landing...
Read More
Oxford Endovascular is chosen as a finalist in the RESI Innovation challenge!

Oxford Endovascular awarded non-dilutive grant funding of up to 2.96 Million Euros to support R&D activities and clinicals

  ‘Next Generation Flow Diverter for the Treatment of Intracranial Aneurysms Delivering Improved Patient Outcomes and Healthcare Cost Savings — OXIFLOW’  ...
Read More
Oxford Endovascular awarded non-dilutive grant funding of up to 2.96 Million Euros to support R&D activities and clinicals

Be Heard Episode #06: Mike Karim | CEO Oxford Endovascular

The Birth of Oxford Endovascular - Interview with Beth Suzanne.
Read More
Be Heard Episode #06: Mike Karim | CEO Oxford Endovascular

Oxford Endovascular kick starts its next fund raise following strong pre-clinical results

Oxford Endovascular kick starts its next fund raise following strong pre-clinical results
Read More
Oxford Endovascular kick starts its next fund raise following strong pre-clinical results

Oxford Endovascular in GLP phase with its brain aneurysm treatment device

Oxford Endovascular in GLP phase with its brain aneurysm treatment device Oxford Endovascular Limited CEO Mike Karim spoke with Proactive...
Read More
Oxford Endovascular in GLP phase with its brain aneurysm treatment device

Oxford Endovascular presents its next investment opportunity as it seeks $8M at the Med Tech Showcase, San Francisco, 9 Jan, 2019

Oxford Endovascular, a spin-out from Oxford University, has used 'origami engineering for the brain' to develop a unique, patented, next-generation...
Read More
Oxford Endovascular presents its next investment opportunity as it seeks $8M at the  Med Tech Showcase, San Francisco, 9 Jan, 2019